首页 > 最新文献

Medical Decision Making最新文献

英文 中文
Implementation of a Decision Aid for Hip and Knee Osteoarthritis in Orthopedics: A Mixed-Methods Process Evaluation. 骨科髋关节和膝关节骨性关节炎决策辅助的实施:混合方法过程评估。
IF 3.1 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-01-01 Epub Date: 2023-10-30 DOI: 10.1177/0272989X231205858
Jeroen Klaas Jacobus Bossen, Julia Aline Wesselink, Ide Christiaan Heyligers, Jesse Jansen

Background: In orthopedics, the use of patient decision aids (ptDAs) is limited. With a mixed-method process evaluation, we investigated patient factors associated with accepting versus declining the use of the ptDA, patients' reasons for declining the ptDA, and clinicians' perceived barriers and facilitators for its use.

Methods: Patients with an indication for joint replacement surgery (N = 153) completed questionnaires measuring demographics, physical functioning, quality of life (EQ-5D-3L), and a visual analog scale (VAS) pain score at 1 time point. Subsequently, their clinician offered them the relevant ptDA. Using a retrospective design, we compared patients who used the ptDA (59%) with patients who declined (41%) on all these measures as well as the chosen treatment. If the use of the ptDA was declined, patients' reasons were recorded by their clinician and analysed (n = 46). To evaluate the experiences of clinicians (n = 5), semistructured interviews were conducted and thematically analyzed. Clinicians who did not use the ptDA substantially (<10 times) were also interviewed (n = 3).

Results: Compared with patients who used the ptDA, patients who declined use had higher VAS pain scores (7.2 v. 6.2, P < .001), reported significantly worse quality of life (on 4 of 6 EQ-5D-3L subscales), and were less likely to receive nonsurgical treatment (4% v. 28%, P < .001). Of the patients who declined to use the ptDA, 46% said they had enough information and felt ready to make a decision without the ptDA. The interviews revealed that clinicians considered the ptDAs most useful for newly diagnosed patients who had not received previous treatment.

Conclusion: These results suggest that the uptake of a ptDA may be improved if it is introduced in the early disease stages of hip and knee osteoarthritis.

Highlights: Patients who declined the use of a patient decision aid (ptDA) for hip and knee osteoarthritis reported more pain and worse quality of life.Most patients who declined to use a ptDA felt sufficiently well informed to make a treatment decision.Patients who declined the ptDA were more likely to have received prior treatment in primary care.Clinicians found the ptDA to be a helpful addition to the consultation, particularly for newly diagnosed patients.

背景:在骨科,患者决策辅助工具(ptDA)的使用是有限的。通过混合方法-过程评估,我们调查了与接受和拒绝使用ptDA相关的患者因素,患者拒绝使用ptDA的原因,以及临床医生对其使用的障碍和促进因素。方法:有关节置换手术适应症的患者(N = 153)在1个时间点完成了测量人口统计、身体功能、生活质量(EQ-5D-3L)和视觉模拟量表(VAS)疼痛评分的问卷调查。随后,他们的临床医生为他们提供了相关的ptDA。使用回顾性设计,我们比较了使用ptDA的患者(59%)和在所有这些指标以及所选治疗方面下降的患者(41%)。如果ptDA的使用减少,则由临床医生记录患者的原因并进行分析(n = 46)。评估临床医生的经验(n = 5) ,进行了半结构化访谈,并进行了主题分析。没有大量使用ptDA的临床医生(n = 3) 结果:与使用ptDA的患者相比,拒绝使用ptDA患者的VAS疼痛评分更高(7.2 vs.6.2,P P 结论:这些结果表明,如果在髋关节和膝关节骨关节炎的早期疾病阶段引入ptDA,可能会提高ptDA的摄取。亮点:拒绝使用患者决策辅助工具(ptDA)治疗髋关节和膝关节骨关节炎的患者报告称疼痛加剧,生活质量下降。大多数拒绝使用ptDA的患者都觉得自己有足够的信息来做出治疗决定。拒绝ptDA的患者更有可能在初级保健中接受过治疗。临床医生发现ptDA是对会诊的有益补充,尤其是对新诊断的患者。
{"title":"Implementation of a Decision Aid for Hip and Knee Osteoarthritis in Orthopedics: A Mixed-Methods Process Evaluation.","authors":"Jeroen Klaas Jacobus Bossen, Julia Aline Wesselink, Ide Christiaan Heyligers, Jesse Jansen","doi":"10.1177/0272989X231205858","DOIUrl":"10.1177/0272989X231205858","url":null,"abstract":"<p><strong>Background: </strong>In orthopedics, the use of patient decision aids (ptDAs) is limited. With a mixed-method process evaluation, we investigated patient factors associated with accepting versus declining the use of the ptDA, patients' reasons for declining the ptDA, and clinicians' perceived barriers and facilitators for its use.</p><p><strong>Methods: </strong>Patients with an indication for joint replacement surgery (<i>N</i> = 153) completed questionnaires measuring demographics, physical functioning, quality of life (EQ-5D-3L), and a visual analog scale (VAS) pain score at 1 time point. Subsequently, their clinician offered them the relevant ptDA. Using a retrospective design, we compared patients who used the ptDA (59%) with patients who declined (41%) on all these measures as well as the chosen treatment. If the use of the ptDA was declined, patients' reasons were recorded by their clinician and analysed (<i>n</i> = 46). To evaluate the experiences of clinicians (<i>n</i> = 5), semistructured interviews were conducted and thematically analyzed. Clinicians who did not use the ptDA substantially (<10 times) were also interviewed (<i>n</i> = 3).</p><p><strong>Results: </strong>Compared with patients who used the ptDA, patients who declined use had higher VAS pain scores (7.2 v. 6.2, <i>P</i> < .001), reported significantly worse quality of life (on 4 of 6 EQ-5D-3L subscales), and were less likely to receive nonsurgical treatment (4% v. 28%, <i>P</i> < .001). Of the patients who declined to use the ptDA, 46% said they had enough information and felt ready to make a decision without the ptDA. The interviews revealed that clinicians considered the ptDAs most useful for newly diagnosed patients who had not received previous treatment.</p><p><strong>Conclusion: </strong>These results suggest that the uptake of a ptDA may be improved if it is introduced in the early disease stages of hip and knee osteoarthritis.</p><p><strong>Highlights: </strong>Patients who declined the use of a patient decision aid (ptDA) for hip and knee osteoarthritis reported more pain and worse quality of life.Most patients who declined to use a ptDA felt sufficiently well informed to make a treatment decision.Patients who declined the ptDA were more likely to have received prior treatment in primary care.Clinicians found the ptDA to be a helpful addition to the consultation, particularly for newly diagnosed patients.</p>","PeriodicalId":49839,"journal":{"name":"Medical Decision Making","volume":" ","pages":"112-122"},"PeriodicalIF":3.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10714711/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71415025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of Mitigation and Control Policies in Realistic Epidemic Models Accounting for Household Transmission Dynamics. 考虑家庭传播动态的现实流行病模型中缓解和控制政策的效果。
IF 3.1 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-01-01 Epub Date: 2023-11-13 DOI: 10.1177/0272989X231205565
Fernando Alarid-Escudero, Jason R Andrews, Jeremy D Goldhaber-Fiebert
<p><strong>Background: </strong>Compartmental infectious disease (ID) models are often used to evaluate nonpharmaceutical interventions (NPIs) and vaccines. Such models rarely separate within-household and community transmission, potentially introducing biases in situations in which multiple transmission routes exist. We formulated an approach that incorporates household structure into ID models, extending the work of House and Keeling.</p><p><strong>Design: </strong>We developed a multicompartment susceptible-exposed-infectious-recovered-susceptible-vaccinated (MC-SEIRSV) modeling framework, allowing nonexponentially distributed duration in exposed and infectious compartments, that tracks within-household and community transmission. We simulated epidemics that varied by community and household transmission rates, waning immunity rate, household size (3 or 5 members), and numbers of exposed and infectious compartments (1-3 each). We calibrated otherwise identical models without household structure to the early phase of each parameter combination's epidemic curve. We compared each model pair in terms of epidemic forecasts and predicted NPI and vaccine impacts on the timing and magnitude of the epidemic peak and its total size. Meta-analytic regressions characterized the relationship between household structure inclusion and the size and direction of biases.</p><p><strong>Results: </strong>Otherwise similar models with and without household structure produced equivalent early epidemic curves. However, forecasts from models without household structure were biased. Without intervention, they were upward biased on peak size and total epidemic size, with biases also depending on the number of exposed and infectious compartments. Model-estimated NPI effects of a 60% reduction in community contacts on peak time and size were systematically overestimated without household structure. Biases were smaller with a 20% reduction NPI. Because vaccination affected both community and household transmission, their biases were smaller.</p><p><strong>Conclusions: </strong>ID models without household structure can produce biased outcomes in settings in which within-household and community transmission differ.</p><p><strong>Highlights: </strong>Infectious disease models rarely separate household transmission from community transmission. The pace of household transmission may differ from community transmission, depends on household size, and can accelerate epidemic growth.Many infectious disease models assume exponential duration distributions for infected states. However, the duration of most infections is not exponentially distributed, and distributional choice alters modeled epidemic dynamics and intervention effectiveness.We propose a mathematical framework for household and community transmission that allows for nonexponential duration times and a suite of interventions and quantified the effect of accounting for household transmission by varying household size and
背景:室状传染病(ID)模型常用于评估非药物干预措施(npi)和疫苗。这种模型很少将家庭和社区内部的传播分开,在存在多种传播途径的情况下可能会引入偏见。我们制定了一种将家庭结构纳入ID模型的方法,扩展了House和Keeling的工作。设计:我们开发了一个多隔室易感-暴露-感染-恢复-易感-接种(MC-SEIRSV)模型框架,允许暴露和感染隔室的非指数分布持续时间,跟踪家庭和社区内的传播。我们模拟的流行病随社区和家庭传播率、免疫力下降率、家庭规模(3或5人)以及暴露和感染隔间数量(每个1-3个)而变化。我们将没有家庭结构的其他相同模型校准到每个参数组合的流行曲线的早期阶段。我们比较了各模型对疫情的预测结果,并预测了NPI和疫苗对疫情高峰时间和规模及其总规模的影响。元分析回归表征了家庭结构包容性与偏差的大小和方向之间的关系。结果:在其他相似的模型中,有和没有家庭结构的模型产生了相同的早期流行曲线。然而,不考虑家庭结构的模型的预测是有偏差的。在没有干预的情况下,它们在峰值大小和总流行大小上向上偏倚,偏差还取决于暴露和感染隔间的数量。在没有家庭结构的情况下,模型估计的社区接触在高峰时间和规模上减少60%的NPI效应被系统地高估了。NPI降低20%,偏倚较小。由于疫苗接种对社区和家庭传播都有影响,因此他们的偏差较小。结论:在家庭内部和社区传播不同的情况下,没有家庭结构的ID模型可能产生有偏差的结果。传染病模型很少将家庭传播与社区传播分开。家庭传播的速度可能不同于社区传播,取决于家庭规模,并可能加速流行病的增长。许多传染病模型假定感染状态的持续时间呈指数分布。然而,大多数感染的持续时间不是指数分布的,分布选择改变了模拟的流行病动态和干预效果。我们提出了一个家庭和社区传播的数学框架,该框架允许非指数持续时间和一套干预措施,并通过改变家庭规模和感染状态的持续时间分布来量化计算家庭传播对模型流行病动力学的影响。如果不把家庭结构包括在内,就会对流行病的整个过程建模产生偏差,并导致在社区环境中采取不同的干预措施所产生的影响。在家庭规模较大的人群中以及传染性持续时间呈非指数分布的疾病中,流行动态更快、更强烈。建模者应考虑明确纳入家庭结构,以量化非药物干预措施(例如,就地避难)的影响。
{"title":"Effects of Mitigation and Control Policies in Realistic Epidemic Models Accounting for Household Transmission Dynamics.","authors":"Fernando Alarid-Escudero, Jason R Andrews, Jeremy D Goldhaber-Fiebert","doi":"10.1177/0272989X231205565","DOIUrl":"10.1177/0272989X231205565","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Compartmental infectious disease (ID) models are often used to evaluate nonpharmaceutical interventions (NPIs) and vaccines. Such models rarely separate within-household and community transmission, potentially introducing biases in situations in which multiple transmission routes exist. We formulated an approach that incorporates household structure into ID models, extending the work of House and Keeling.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design: &lt;/strong&gt;We developed a multicompartment susceptible-exposed-infectious-recovered-susceptible-vaccinated (MC-SEIRSV) modeling framework, allowing nonexponentially distributed duration in exposed and infectious compartments, that tracks within-household and community transmission. We simulated epidemics that varied by community and household transmission rates, waning immunity rate, household size (3 or 5 members), and numbers of exposed and infectious compartments (1-3 each). We calibrated otherwise identical models without household structure to the early phase of each parameter combination's epidemic curve. We compared each model pair in terms of epidemic forecasts and predicted NPI and vaccine impacts on the timing and magnitude of the epidemic peak and its total size. Meta-analytic regressions characterized the relationship between household structure inclusion and the size and direction of biases.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Otherwise similar models with and without household structure produced equivalent early epidemic curves. However, forecasts from models without household structure were biased. Without intervention, they were upward biased on peak size and total epidemic size, with biases also depending on the number of exposed and infectious compartments. Model-estimated NPI effects of a 60% reduction in community contacts on peak time and size were systematically overestimated without household structure. Biases were smaller with a 20% reduction NPI. Because vaccination affected both community and household transmission, their biases were smaller.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;ID models without household structure can produce biased outcomes in settings in which within-household and community transmission differ.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Highlights: &lt;/strong&gt;Infectious disease models rarely separate household transmission from community transmission. The pace of household transmission may differ from community transmission, depends on household size, and can accelerate epidemic growth.Many infectious disease models assume exponential duration distributions for infected states. However, the duration of most infections is not exponentially distributed, and distributional choice alters modeled epidemic dynamics and intervention effectiveness.We propose a mathematical framework for household and community transmission that allows for nonexponential duration times and a suite of interventions and quantified the effect of accounting for household transmission by varying household size and","PeriodicalId":49839,"journal":{"name":"Medical Decision Making","volume":" ","pages":"5-17"},"PeriodicalIF":3.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89720274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessing the Value of Provider-Facing Digital Health Technologies Used in Chronic Disease Management: Toward a Value Framework Based on Multistakeholder Perceptions. 评估面向提供者的数字健康技术在慢性病管理中的价值:基于多利益相关者感知的价值框架。
IF 3.1 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-01-01 Epub Date: 2023-10-26 DOI: 10.1177/0272989X231206803
Caitlin Main, Madeleine Haig, Danitza Chavez, Panos Kanavos
<p><strong>Objectives: </strong>Hardly any value frameworks exist that are focused on provider-facing digital health technologies (DHTs) for managing chronic disease with diverse stakeholder participation in their creation. Our study aimed to 1) understanding different stakeholder opinions on where value lies in provider-facing technologies and 2) create a comprehensive value assessment framework for DHT assessment.</p><p><strong>Methods: </strong>Mixed-methods comprising both primary and secondary evidence were used. A scoping review enabled a greater understanding of the evidence base and generated the initial indicators. Thirty-four indicators were proposed within 6 value domains: health inequalities (3), data rights and governance (6), technical and security characteristics (6), clinical characteristics (7), economic characteristics (9), and user preferences (3). Subsequently, a 3-round Web-Delphi was conducted to rate the indicators' importance in the context of technology assessment and determine whether there was consensus.</p><p><strong>Results: </strong>The framework was adapted to 45 indicators based on participant contributions in round 1 and delivered 16 stable indicators with consensus after rounds 2 and 3. Twenty-nine indicators showed instability and/or dissensus, particularly the data rights domain, in which all 5 indicators were unstable, showcasing the novelty of the concept of data rights. Significant instability between <i>important</i> and <i>very important</i> ratings was present within stakeholder groups, particularly clinicians and policy experts, indicating they were unsure how different aspects should be valued.</p><p><strong>Conclusions: </strong>Our study provides a comprehensive value assessment framework for assessing provider-facing DHTs incorporating diverse stakeholder perspectives. Instability for specific indicators was expected due to the novelty of data and analytics integration in health technologies and their assessment. Further work is needed to ensure that, across all types of stakeholders, there is a clear understanding of the potential impacts of provider-facing DHTs.</p><p><strong>Highlights: </strong>Current health technology assessment (HTA) methods may not be well suited for evaluating digital health technologies (DHTs) because of their complexity and wide-ranging impact on the health system.This article adds to the literature by exploring a wide range of stakeholder opinions on the value of provider-facing DHTs, creating a holistic value framework for these technologies, and highlighting areas in which further discussions are needed to align stakeholders on DHTs' value attributes.A Web-based Delphi co-creation approach was used involving key stakeholders from throughout the digital health space to generate a widely applicable value framework for assessing provider-facing DHTs. The stakeholders include patients, health care professionals, supply-side actors, decision makers, and academia from the Uni
目标:几乎没有任何价值框架专注于面向提供者的数字健康技术(DHT),以管理慢性病,并让不同的利益相关者参与其创建。我们的研究旨在1)了解不同利益相关者对面向提供商的技术价值所在的看法,2)为DHT评估创建一个全面的价值评估框架。方法:采用包括主要证据和次要证据的混合方法。范围审查使人们能够更好地了解证据基础,并产生初步指标。在6个价值领域内提出了34个指标:健康不平等(3)、数据权利和治理(6)、技术和安全特征(6),临床特征(7)、经济特征(9)和用户偏好(3)。随后,进行了三轮网络德尔菲,对指标在技术评估中的重要性进行评分,并确定是否达成共识。结果:该框架在第一轮中根据参与者的贡献调整了45个指标,并在第二轮和第三轮之后达成了16个稳定的指标。29项指标显示不稳定和/或不一致,特别是数据权领域,其中所有5项指标都不稳定,显示了数据权概念的新颖性。利益相关者群体,特别是临床医生和政策专家,在重要评级和非常重要评级之间存在显著的不稳定性,这表明他们不确定应该如何评估不同方面。结论:我们的研究为评估面向提供者的DHT提供了一个全面的价值评估框架,结合了不同的利益相关者的观点。由于卫生技术及其评估中数据和分析集成的新颖性,预计特定指标不稳定。需要进一步的工作,以确保所有类型的利益相关者都清楚地了解面向提供者的数字健康技术的潜在影响。亮点:当前的健康技术评估(HTA)方法可能不太适合评估数字健康技术,因为其复杂性和对卫生系统的广泛影响。这篇文章通过探索利益相关者对面向提供商的DHT价值的广泛意见,为这些技术创建一个整体的价值框架,并强调需要进一步讨论的领域,以使利益相关者在DHT的价值属性上保持一致,从而补充了文献。使用了一种基于网络的Delphi共创方法,涉及整个数字健康领域的关键利益相关者,以生成一个广泛适用的价值框架,用于评估面向提供者的DHT。利益相关者包括来自美国、英国和德国的患者、医疗保健专业人员、供应方参与者、决策者和学术界。利益相关者和价值领域之间存在高度不稳定,这表明评估提供者面临的DHT及其对卫生系统的影响是新颖的。
{"title":"Assessing the Value of Provider-Facing Digital Health Technologies Used in Chronic Disease Management: Toward a Value Framework Based on Multistakeholder Perceptions.","authors":"Caitlin Main, Madeleine Haig, Danitza Chavez, Panos Kanavos","doi":"10.1177/0272989X231206803","DOIUrl":"10.1177/0272989X231206803","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objectives: &lt;/strong&gt;Hardly any value frameworks exist that are focused on provider-facing digital health technologies (DHTs) for managing chronic disease with diverse stakeholder participation in their creation. Our study aimed to 1) understanding different stakeholder opinions on where value lies in provider-facing technologies and 2) create a comprehensive value assessment framework for DHT assessment.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Mixed-methods comprising both primary and secondary evidence were used. A scoping review enabled a greater understanding of the evidence base and generated the initial indicators. Thirty-four indicators were proposed within 6 value domains: health inequalities (3), data rights and governance (6), technical and security characteristics (6), clinical characteristics (7), economic characteristics (9), and user preferences (3). Subsequently, a 3-round Web-Delphi was conducted to rate the indicators' importance in the context of technology assessment and determine whether there was consensus.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The framework was adapted to 45 indicators based on participant contributions in round 1 and delivered 16 stable indicators with consensus after rounds 2 and 3. Twenty-nine indicators showed instability and/or dissensus, particularly the data rights domain, in which all 5 indicators were unstable, showcasing the novelty of the concept of data rights. Significant instability between &lt;i&gt;important&lt;/i&gt; and &lt;i&gt;very important&lt;/i&gt; ratings was present within stakeholder groups, particularly clinicians and policy experts, indicating they were unsure how different aspects should be valued.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Our study provides a comprehensive value assessment framework for assessing provider-facing DHTs incorporating diverse stakeholder perspectives. Instability for specific indicators was expected due to the novelty of data and analytics integration in health technologies and their assessment. Further work is needed to ensure that, across all types of stakeholders, there is a clear understanding of the potential impacts of provider-facing DHTs.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Highlights: &lt;/strong&gt;Current health technology assessment (HTA) methods may not be well suited for evaluating digital health technologies (DHTs) because of their complexity and wide-ranging impact on the health system.This article adds to the literature by exploring a wide range of stakeholder opinions on the value of provider-facing DHTs, creating a holistic value framework for these technologies, and highlighting areas in which further discussions are needed to align stakeholders on DHTs' value attributes.A Web-based Delphi co-creation approach was used involving key stakeholders from throughout the digital health space to generate a widely applicable value framework for assessing provider-facing DHTs. The stakeholders include patients, health care professionals, supply-side actors, decision makers, and academia from the Uni","PeriodicalId":49839,"journal":{"name":"Medical Decision Making","volume":" ","pages":"28-41"},"PeriodicalIF":3.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10714693/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50163436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Attitudes on Equal Health Care Access versus Efficient Clinical Decisions across a Not-for-Profit Health Care System. 在非营利性医疗保健系统中,对平等医疗保健机会与有效临床决策的态度。
IF 3.1 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-01-01 Epub Date: 2023-10-24 DOI: 10.1177/0272989X231206750
Ganeev Singh, Laura Corlin, Paul R Beninger, Peter J Neumann, Marcia M Boumil, Shreya Mehta, Deeb N Salem
<p><strong>Background: </strong>Professional roles within a hospital system may influence attitudes behind clinical decisions.</p><p><strong>Objective: </strong>To determine participants' preferences about clinical decisions that either value equal health care access or efficiency.</p><p><strong>Design: </strong>Deidentified survey asking participants to choose between offering a low-cost screening test to a whole population ("equal access") or a more sensitive, expensive test that could be given to only half of the population but resulting in 10% more avoided deaths ("efficient"). Data collection took place from August 18, 2021, to January 24, 2022. Study 1644 was determined to be exempt by Tufts Health Sciences Institutional Review Board (IRB).</p><p><strong>Setting: </strong>Tufts Medicine Healthcare System.</p><p><strong>Participants: </strong>Approximately 15,000 hospital employees received an e-mail from the Tufts Medicine Senior Vice President of Academic Integration.</p><p><strong>Measurements: </strong>Analysis of survey responses with chi-square and 1-sample <i>t</i> tests to determine the proportion who chose each option. Logistic regression models fit to examine relationships between professional role and test choice.</p><p><strong>Results: </strong>A total of 1,346 participants completed the survey (∼9.0% response rate). Overall, approximately equal percentages of respondents chose the "equal access" (48%) and "efficient" option (52%). However, gender, professional role (categorical), and clinical role (dichotomous) were significantly associated with test choice. For example, among those in nonclinical roles, women were more likely than men to choose equal health care access. In multivariable analyses, having clinical roles was significantly associated with 1.73 times the likelihood of choosing equal access (95% confidence interval = 1.33-2.25).</p><p><strong>Limitations: </strong>Generalizability concerns and survey question wording limit the study results.</p><p><strong>Conclusion: </strong>Clinicians were more likely than nonclinicians to choose the equal health care access option, and health care administrators were more likely to choose efficiency. These differing attitudes can affect patient care and health care quality.</p><p><strong>Highlights: </strong>Divergent preferences of valuing equal health care access and efficiency may be in conflict during clinical decision making.In this cross-sectional study that included 1,346 participants, approximately equal percentages of respondents chose the "equal access" (48%) and "efficient" option (52%), a nonsignificant difference. However, gender, professional role (categorical), and clinical role (dichotomous) were significantly associated with test choiceSince clinicians were more likely than nonclinicians to choose the equal health care access option and health care administrators were more likely to choose efficiency, these differing attitudes can affect patient care and health ca
背景:医院系统中的专业角色可能会影响临床决策背后的态度。目的:确定参与者对重视平等医疗服务或效率的临床决策的偏好。设计:非身份调查要求参与者在向全体人群提供低成本的筛查测试(“平等获取”)或更敏感、更昂贵的测试之间做出选择,该测试只能为一半的人群提供,但可避免10%以上的死亡(“有效”)。数据收集时间为2021年8月18日至2022年1月24日。研究1644被塔夫茨健康科学机构审查委员会(IRB)确定为豁免。设置:塔夫茨医学医疗保健系统。参与者:大约15000名医院员工收到了塔夫茨医学院学术整合高级副总裁的电子邮件。测量:用卡方和单样本t检验分析调查结果,以确定选择的比例每个选项。逻辑回归模型适用于检验职业角色和测试选择之间的关系。结果:共有1346名参与者完成了调查(~9.0%的应答率)。总体而言,选择“平等机会”(48%)和“高效”选项(52%)的受访者比例大致相等。然而,性别、专业角色(分类)和临床角色(二分法)与测试选择显著相关。例如,在非临床角色中,女性比男性更有可能选择平等的医疗服务。在多变量分析中,具有临床角色与选择同等途径的可能性的1.73倍显著相关(95%置信区间 = 1.33-2.25)。局限性:泛化问题和调查问题措辞限制了研究结果。结论:临床医生比非临床医生更有可能选择平等的医疗保健服务,医疗保健管理者更有可能选择效率。这些不同的态度会影响患者护理和医疗质量。亮点:在临床决策过程中,重视平等医疗保健机会和效率的不同偏好可能会发生冲突。在这项包括1346名参与者的横断面研究中,选择“平等机会”(48%)和“有效”选项(52%)的受访者比例大致相等,差异不显著。然而,性别、专业角色(分类)和临床角色(二分法)与测试选择显著相关。由于临床医生比非临床医生更有可能选择平等的医疗保健服务,医疗保健管理人员更有可能选择效率,这些不同的态度会影响患者护理和医疗保健质量。
{"title":"Attitudes on Equal Health Care Access versus Efficient Clinical Decisions across a Not-for-Profit Health Care System.","authors":"Ganeev Singh, Laura Corlin, Paul R Beninger, Peter J Neumann, Marcia M Boumil, Shreya Mehta, Deeb N Salem","doi":"10.1177/0272989X231206750","DOIUrl":"10.1177/0272989X231206750","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Professional roles within a hospital system may influence attitudes behind clinical decisions.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To determine participants' preferences about clinical decisions that either value equal health care access or efficiency.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design: &lt;/strong&gt;Deidentified survey asking participants to choose between offering a low-cost screening test to a whole population (\"equal access\") or a more sensitive, expensive test that could be given to only half of the population but resulting in 10% more avoided deaths (\"efficient\"). Data collection took place from August 18, 2021, to January 24, 2022. Study 1644 was determined to be exempt by Tufts Health Sciences Institutional Review Board (IRB).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Setting: &lt;/strong&gt;Tufts Medicine Healthcare System.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Participants: &lt;/strong&gt;Approximately 15,000 hospital employees received an e-mail from the Tufts Medicine Senior Vice President of Academic Integration.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Measurements: &lt;/strong&gt;Analysis of survey responses with chi-square and 1-sample &lt;i&gt;t&lt;/i&gt; tests to determine the proportion who chose each option. Logistic regression models fit to examine relationships between professional role and test choice.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 1,346 participants completed the survey (∼9.0% response rate). Overall, approximately equal percentages of respondents chose the \"equal access\" (48%) and \"efficient\" option (52%). However, gender, professional role (categorical), and clinical role (dichotomous) were significantly associated with test choice. For example, among those in nonclinical roles, women were more likely than men to choose equal health care access. In multivariable analyses, having clinical roles was significantly associated with 1.73 times the likelihood of choosing equal access (95% confidence interval = 1.33-2.25).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Limitations: &lt;/strong&gt;Generalizability concerns and survey question wording limit the study results.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Clinicians were more likely than nonclinicians to choose the equal health care access option, and health care administrators were more likely to choose efficiency. These differing attitudes can affect patient care and health care quality.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Highlights: &lt;/strong&gt;Divergent preferences of valuing equal health care access and efficiency may be in conflict during clinical decision making.In this cross-sectional study that included 1,346 participants, approximately equal percentages of respondents chose the \"equal access\" (48%) and \"efficient\" option (52%), a nonsignificant difference. However, gender, professional role (categorical), and clinical role (dichotomous) were significantly associated with test choiceSince clinicians were more likely than nonclinicians to choose the equal health care access option and health care administrators were more likely to choose efficiency, these differing attitudes can affect patient care and health ca","PeriodicalId":49839,"journal":{"name":"Medical Decision Making","volume":" ","pages":"18-27"},"PeriodicalIF":3.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50159082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Blurred Lines of HTA Agency Decision Making. HTA机构决策的模糊界限。
IF 3.1 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-01-01 Epub Date: 2023-11-10 DOI: 10.1177/0272989X231208443
Grace Mitchell, Sreeram V Ramagopalan
{"title":"The Blurred Lines of HTA Agency Decision Making.","authors":"Grace Mitchell, Sreeram V Ramagopalan","doi":"10.1177/0272989X231208443","DOIUrl":"10.1177/0272989X231208443","url":null,"abstract":"","PeriodicalId":49839,"journal":{"name":"Medical Decision Making","volume":" ","pages":"3-4"},"PeriodicalIF":3.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72211626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient Reasoning: Patients' and Care Partners' Perceptions of Diagnostic Accuracy in Emergency Care. 患者推理:患者和护理伙伴对急诊护理诊断准确性的看法。
IF 3.1 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-01-01 Epub Date: 2023-11-15 DOI: 10.1177/0272989X231207829
Vadim Dukhanin, Kathryn M McDonald, Natalia Gonzalez, Kelly T Gleason

Objectives: In the context of validating a measure of patient report specific to diagnostic accuracy in emergency department or urgent care, this study investigates patients' and care partners' perceptions of diagnoses as accurate and explores variations in how they reason while they assess accuracy.

Methods: In February 2022, we surveyed a national panel of adults who had an emergency department or urgent care visit in the past month to test a patient-reported measure. As part of the survey validation, we asked for free-text responses about why the respondents indicated their (dis)agreement with 2 statements comprising patient-reported diagnostic accuracy: 1) the explanation they received of the health problem was true and 2) the explanation described what to expect of the health problem. Those paired free-text responses were qualitatively analyzed according to themes created inductively.

Results: A total of 1,116 patients and care partners provided 982 responses coded into 10 themes, which were further grouped into 3 reasoning types. Almost one-third (32%) of respondents used only corroborative reasoning in assessing the accuracy of the health problem explanation (alignment of the explanation with either test results, patients' subsequent health trajectory, their medical knowledge, symptoms, or another doctor's opinion), 26% used only perception-based reasoning (perceptions of diagnostic process, uncertainty around the explanation received, or clinical team's attitudes), and 27% used both types of reasoning. The remaining 15% used general beliefs or nonexplicated logic (used only about accurate diagnoses) and combinations of general reasoning with perception-based and corroborative.

Conclusions: Patients and care partners used multifaceted reasoning in their assessment of diagnostic accuracy.

Implications: As health care shifts toward meaningful diagnostic co-production and shared decision making, in-depth understanding of variations in patient reasoning and mental models informs use in clinical practice.

Highlights: An analysis of 982 responses examined how patients and care partners reason about the accuracy of diagnoses they received in emergency or urgent care.In reasoning, people used their perception of the process and whether the diagnosis matched other factual information they have.We introduce "patient reasoning" in the diagnostic measurement context as an area of further research to inform diagnostic shared decision making and co-production of health.

目的:在验证急诊科或紧急护理中特定诊断准确性的患者报告测量的背景下,本研究调查了患者和护理伙伴对诊断准确性的看法,并探讨了他们在评估准确性时如何推理的变化。方法:在2022年2月,我们调查了一个在过去一个月去过急诊科或急诊就诊的全国成年人小组,以测试一项患者报告的措施。作为调查验证的一部分,我们要求自由文本回答为什么受访者表示他们(不)同意包括患者报告的诊断准确性的2个陈述:1)他们收到的健康问题的解释是真实的,2)解释描述了对健康问题的期望。根据归纳产生的主题对配对的自由文本回答进行定性分析。结果:共有1116名患者和护理伙伴提供了982个回答,编码为10个主题,并进一步分为3种推理类型。几乎三分之一(32%)的受访者在评估健康问题解释的准确性时仅使用确证推理(将解释与测试结果、患者随后的健康轨迹、他们的医学知识、症状或另一位医生的意见保持一致),26%仅使用基于感知的推理(对诊断过程的感知、所接受解释的不确定性或临床团队的态度),27%使用两种类型的推理。剩下的15%使用一般信念或不明确的逻辑(仅用于准确的诊断),以及将一般推理与基于感知和确证的推理相结合。结论:患者和护理伙伴在评估诊断准确性时使用多方面推理。随着医疗保健转向有意义的诊断合作生产和共同决策,深入了解患者推理和心理模型的变化,为临床实践提供信息。重点:对982份回复的分析检查了患者和护理伙伴如何判断他们在急诊或紧急护理中得到的诊断的准确性。在推理中,人们使用他们对过程的感知,以及诊断是否与他们拥有的其他事实信息相匹配。我们在诊断测量背景下引入“患者推理”,作为进一步研究的领域,为诊断共享决策和健康的共同生产提供信息。
{"title":"Patient Reasoning: Patients' and Care Partners' Perceptions of Diagnostic Accuracy in Emergency Care.","authors":"Vadim Dukhanin, Kathryn M McDonald, Natalia Gonzalez, Kelly T Gleason","doi":"10.1177/0272989X231207829","DOIUrl":"10.1177/0272989X231207829","url":null,"abstract":"<p><strong>Objectives: </strong>In the context of validating a measure of patient report specific to diagnostic accuracy in emergency department or urgent care, this study investigates patients' and care partners' perceptions of diagnoses as accurate and explores variations in how they reason while they assess accuracy.</p><p><strong>Methods: </strong>In February 2022, we surveyed a national panel of adults who had an emergency department or urgent care visit in the past month to test a patient-reported measure. As part of the survey validation, we asked for free-text responses about why the respondents indicated their (dis)agreement with 2 statements comprising patient-reported diagnostic accuracy: 1) the explanation they received of the health problem was true and 2) the explanation described what to expect of the health problem. Those paired free-text responses were qualitatively analyzed according to themes created inductively.</p><p><strong>Results: </strong>A total of 1,116 patients and care partners provided 982 responses coded into 10 themes, which were further grouped into 3 reasoning types. Almost one-third (32%) of respondents used only corroborative reasoning in assessing the accuracy of the health problem explanation (alignment of the explanation with either test results, patients' subsequent health trajectory, their medical knowledge, symptoms, or another doctor's opinion), 26% used only perception-based reasoning (perceptions of diagnostic process, uncertainty around the explanation received, or clinical team's attitudes), and 27% used both types of reasoning. The remaining 15% used general beliefs or nonexplicated logic (used only about accurate diagnoses) and combinations of general reasoning with perception-based and corroborative.</p><p><strong>Conclusions: </strong>Patients and care partners used multifaceted reasoning in their assessment of diagnostic accuracy.</p><p><strong>Implications: </strong>As health care shifts toward meaningful diagnostic co-production and shared decision making, in-depth understanding of variations in patient reasoning and mental models informs use in clinical practice.</p><p><strong>Highlights: </strong>An analysis of 982 responses examined how patients and care partners reason about the accuracy of diagnoses they received in emergency or urgent care.In reasoning, people used their perception of the process and whether the diagnosis matched other factual information they have.We introduce \"patient reasoning\" in the diagnostic measurement context as an area of further research to inform diagnostic shared decision making and co-production of health.</p>","PeriodicalId":49839,"journal":{"name":"Medical Decision Making","volume":" ","pages":"102-111"},"PeriodicalIF":3.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10712203/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"107592592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessing and Understanding Reactance, Self-Exemption, Disbelief, Source Derogation and Information Conflict in Reaction to Overdiagnosis in Mammography Screening: Scale Development and Preliminary Validation. 评估和理解乳腺造影筛查中对过度诊断反应的反应、自我豁免、不信任、来源减损和信息冲突:量表开发和初步验证。
IF 3.6 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-10-01 Epub Date: 2023-09-14 DOI: 10.1177/0272989X231195603
Laura D Scherer, Krithika Suresh, Carmen L Lewis, Kirsten J McCaffery, Jolyn Hersch, Joseph N Cappella, Brad Morse, Channing E Tate, Bridget S Mosley, Sarah Schmiege, Marilyn M Schapira

Purpose: Overdiagnosis is a concept central to making informed breast cancer screening decisions, and yet some people may react to overdiagnosis with doubt and skepticism. The present research assessed 4 related reactions to overdiagnosis: reactance, self-exemption, disbelief, and source derogation (REDS). The degree to which the concept of overdiagnosis conflicts with participants' prior beliefs and health messages (information conflict) was also assessed as a potential antecedent of REDS. We developed a scale to assess these reactions, evaluated how those reactions are related, and identified their potential implications for screening decision making.

Methods: Female participants aged 39 to 49 years read information about overdiagnosis in mammography screening and completed survey questions assessing their reactions to that information. We used a multidimensional theoretical framework to assess dimensionality and overall domain-specific internal consistency of the REDS and Information Conflict questions. Exploratory and confirmatory factor analyses were performed using data randomly split into a training set and test set. Correlations between REDS, screening intentions, and other outcomes were evaluated.

Results: Five-hundred twenty-five participants completed an online survey. Exploratory and confirmatory factor analyses identified that Reactance, Self Exemption, Disbelief, Source Derogation, and Information Conflict represent unique constructs. A reduced 20-item scale was created by selecting 4 items per construct, which showed good model fit. Reactance, Disbelief, and Source Derogation were associated with lower intent to use information about overdiagnosis in decision making and the belief that informing people about overdiagnosis is unimportant.

Conclusions: REDS and Information Conflict are distinct but correlated constructs that are common reactions to overdiagnosis. Some of these reactions may have negative implications for making informed screening decisions.

Highlights: Overdiagnosis is a concept central to making informed breast cancer screening decisions, and yet when provided information about overdiagnosis, some people are skeptical.This research developed a measure that assessed different ways in which people might express skepticism about overdiagnosis (reactance, self-exemption, disbelief, source derogation) and also the perception that overdiagnosis conflicts with prior knowledge and health messages (information conflict).These different reactions are distinct but correlated and are common reactions when people learn about overdiagnosis.Reactance, disbelief, and source derogation are associated with lower intent to use information about overdiagnosis in decision making as well as the belief that informing people about overdiagnosis is unimportant.

目的:过度诊断是做出知情的癌症筛查决定的核心概念,但有些人可能会对过度诊断产生怀疑和怀疑。本研究评估了过度诊断的4种相关反应:抗拒、自我豁免、怀疑和来源减损(REDS)。过度诊断的概念与参与者先前的信念和健康信息冲突的程度(信息冲突)也被评估为REDS的潜在先行因素。我们开发了一个评估这些反应的量表,评估了这些反应之间的关系,并确定了它们对筛查决策的潜在影响。方法:39至49岁的女性参与者 多年来,他们阅读了有关乳腺钼靶筛查过度诊断的信息,并完成了评估他们对这些信息反应的调查问题。我们使用多维理论框架来评估REDS和信息冲突问题的维度和特定领域的整体内部一致性。使用随机分为训练集和测试集的数据进行探索性和验证性因素分析。评估REDS、筛查意向和其他结果之间的相关性。结果:五百二十五名参与者完成了一项在线调查。探索性和验证性因素分析表明,反应、自我豁免、不信任、来源减损和信息冲突代表了独特的结构。通过每个构造选择4个项目来创建缩减的20个项目的规模,这显示出良好的模型拟合。反应、不信任和来源减损与决策中使用过度诊断信息的意愿较低以及认为告知人们过度诊断不重要有关。结论:REDS和信息冲突是不同但相关的结构,是对过度诊断的常见反应。其中一些反应可能会对做出知情的筛查决定产生负面影响。要点:过度诊断是做出知情的癌症筛查决定的核心概念,但当提供有关过度诊断的信息时,一些人持怀疑态度。这项研究开发了一种测量方法,评估了人们对过度诊断表示怀疑的不同方式(抗拒、自我豁免、怀疑、来源减损),以及过度诊断与先前知识和健康信息冲突的看法(信息冲突)关于过度诊断。反应、怀疑和来源减损与决策中使用过度诊断信息的意愿较低以及认为告知人们过度诊断不重要有关。
{"title":"Assessing and Understanding Reactance, Self-Exemption, Disbelief, Source Derogation and Information Conflict in Reaction to Overdiagnosis in Mammography Screening: Scale Development and Preliminary Validation.","authors":"Laura D Scherer, Krithika Suresh, Carmen L Lewis, Kirsten J McCaffery, Jolyn Hersch, Joseph N Cappella, Brad Morse, Channing E Tate, Bridget S Mosley, Sarah Schmiege, Marilyn M Schapira","doi":"10.1177/0272989X231195603","DOIUrl":"10.1177/0272989X231195603","url":null,"abstract":"<p><strong>Purpose: </strong>Overdiagnosis is a concept central to making informed breast cancer screening decisions, and yet some people may react to overdiagnosis with doubt and skepticism. The present research assessed 4 related reactions to overdiagnosis: reactance, self-exemption, disbelief, and source derogation (REDS). The degree to which the concept of overdiagnosis conflicts with participants' prior beliefs and health messages (information conflict) was also assessed as a potential antecedent of REDS. We developed a scale to assess these reactions, evaluated how those reactions are related, and identified their potential implications for screening decision making.</p><p><strong>Methods: </strong>Female participants aged 39 to 49 years read information about overdiagnosis in mammography screening and completed survey questions assessing their reactions to that information. We used a multidimensional theoretical framework to assess dimensionality and overall domain-specific internal consistency of the REDS and Information Conflict questions. Exploratory and confirmatory factor analyses were performed using data randomly split into a training set and test set. Correlations between REDS, screening intentions, and other outcomes were evaluated.</p><p><strong>Results: </strong>Five-hundred twenty-five participants completed an online survey. Exploratory and confirmatory factor analyses identified that Reactance, Self Exemption, Disbelief, Source Derogation, and Information Conflict represent unique constructs. A reduced 20-item scale was created by selecting 4 items per construct, which showed good model fit. Reactance, Disbelief, and Source Derogation were associated with lower intent to use information about overdiagnosis in decision making and the belief that informing people about overdiagnosis is unimportant.</p><p><strong>Conclusions: </strong>REDS and Information Conflict are distinct but correlated constructs that are common reactions to overdiagnosis. Some of these reactions may have negative implications for making informed screening decisions.</p><p><strong>Highlights: </strong>Overdiagnosis is a concept central to making informed breast cancer screening decisions, and yet when provided information about overdiagnosis, some people are skeptical.This research developed a measure that assessed different ways in which people might express skepticism about overdiagnosis (reactance, self-exemption, disbelief, source derogation) and also the perception that overdiagnosis conflicts with prior knowledge and health messages (information conflict).These different reactions are distinct but correlated and are common reactions when people learn about overdiagnosis.Reactance, disbelief, and source derogation are associated with lower intent to use information about overdiagnosis in decision making as well as the belief that informing people about overdiagnosis is unimportant.</p>","PeriodicalId":49839,"journal":{"name":"Medical Decision Making","volume":" ","pages":"789-802"},"PeriodicalIF":3.6,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10843591/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10579294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Collecting Physicians' Preferences on Medical Devices: Are We Doing It Right? Evidence from Italian Orthopedists Using 2 Different Stated Preference Methods. 收集医生对医疗器械的偏好:我们做得对吗?意大利骨科医生使用两种不同的陈述偏好方法提供的证据。
IF 3.6 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-10-01 Epub Date: 2023-10-14 DOI: 10.1177/0272989X231201805
Patrizio Armeni, Michela Meregaglia, Ludovica Borsoi, Giuditta Callea, Aleksandra Torbica, Francesco Benazzo, Rosanna Tarricone

Objectives: Physician preference items (PPIs) are high-cost medical devices for which clinicians express firm preferences with respect to a particular manufacturer or product. This study aims to identify the most important factors in the choice of new PPIs (hip or knee prosthesis) and infer about the existence of possible response biases in using 2 alternative stated preference techniques.

Methods: Six key attributes with 3 levels each were identified based on a literature review and clinical experts' opinions. An online survey was administered to Italian hospital orthopedists using type 1 best-worst scaling (BWS) and binary discrete choice experiment (DCE). BWS data were analyzed through descriptive statistics and conditional logit model. A mixed logit regression model was applied to DCE data, and willingness-to-pay (WTP) was estimated. All analyses were conducted using Stata 16.

Results: A sample of 108 orthopedists were enrolled. In BWS, the most important attribute was "clinical evidence," followed by "quality of products," while the least relevant items were "relationship with the sales representative" and "cost." DCE results suggested instead that orthopedists prefer high-quality products with robust clinical evidence, positive health technology assessment recommendation and affordable cost, and for which they have a consolidated experience of use and a good relationship with the sales representative.

Conclusions: The elicitation of preferences for PPIs using alternative methods can lead to different results. The BWS of type 1, which is similar to a ranking exercise, seems to be more affected by acquiescent responding and social desirability than the DCE, which introduces tradeoffs in the choice task and is likely to reveal more about true preferences.

Highlights: Physician preference items (PPIs) are medical devices particularly exposed to physicians' choice with regard to type of product and supplier.Some established techniques of collecting preferences can be affected by response biases such as acquiescent responding and social desirability.Discrete choice experiments, introducing more complex tradeoffs in the choice task, are likely to mitigate such biases and reveal true physicians' preferences for PPIs.

目的:医师偏好项目(PPI)是指临床医生对特定制造商或产品表示坚定偏好的高成本医疗设备。本研究旨在确定选择新PPI(髋关节或膝关节假体)的最重要因素,并推断在使用2种替代的既定偏好技术时可能存在的反应偏差。方法:根据文献综述和临床专家的意见,确定6个关键属性,每个属性有3个级别。使用1型最佳-最差量表(BWS)和二元离散选择实验(DCE)对意大利医院骨科医生进行了在线调查。采用描述性统计和条件logit模型对BWS数据进行分析。将混合logit回归模型应用于DCE数据,并估计支付意愿(WTP)。所有分析均使用Stata 16进行。结果:入选108名骨科医生。在BWS中,最重要的属性是“临床证据”,其次是“产品质量”,而最不相关的项目是“与销售代表的关系”和“成本”。DCE的结果表明,骨科医生更喜欢具有强有力的临床证据、积极的健康技术评估建议和可负担的成本的高质量产品,他们有着丰富的使用经验,并与销售代表保持着良好的关系。结论:使用替代方法激发PPI的偏好可能会导致不同的结果。类型1的BWS类似于排名练习,似乎比DCE更受默许反应和社会愿望的影响,DCE在选择任务中引入了权衡,并可能揭示更多关于真实偏好的信息。亮点:医生偏好项目(PPI)是指在产品类型和供应商方面特别容易受到医生选择的医疗器械。一些收集偏好的既定技术可能会受到反应偏见的影响,如默许反应和社会期望。离散选择实验,在选择任务中引入更复杂的权衡,可能会减轻这种偏见,并揭示医生对PPI的真实偏好。
{"title":"Collecting Physicians' Preferences on Medical Devices: Are We Doing It Right? Evidence from Italian Orthopedists Using 2 Different Stated Preference Methods.","authors":"Patrizio Armeni, Michela Meregaglia, Ludovica Borsoi, Giuditta Callea, Aleksandra Torbica, Francesco Benazzo, Rosanna Tarricone","doi":"10.1177/0272989X231201805","DOIUrl":"10.1177/0272989X231201805","url":null,"abstract":"<p><strong>Objectives: </strong>Physician preference items (PPIs) are high-cost medical devices for which clinicians express firm preferences with respect to a particular manufacturer or product. This study aims to identify the most important factors in the choice of new PPIs (hip or knee prosthesis) and infer about the existence of possible response biases in using 2 alternative stated preference techniques.</p><p><strong>Methods: </strong>Six key attributes with 3 levels each were identified based on a literature review and clinical experts' opinions. An online survey was administered to Italian hospital orthopedists using type 1 best-worst scaling (BWS) and binary discrete choice experiment (DCE). BWS data were analyzed through descriptive statistics and conditional logit model. A mixed logit regression model was applied to DCE data, and willingness-to-pay (WTP) was estimated. All analyses were conducted using Stata 16.</p><p><strong>Results: </strong>A sample of 108 orthopedists were enrolled. In BWS, the most important attribute was \"clinical evidence,\" followed by \"quality of products,\" while the least relevant items were \"relationship with the sales representative\" and \"cost.\" DCE results suggested instead that orthopedists prefer high-quality products with robust clinical evidence, positive health technology assessment recommendation and affordable cost, and for which they have a consolidated experience of use and a good relationship with the sales representative.</p><p><strong>Conclusions: </strong>The elicitation of preferences for PPIs using alternative methods can lead to different results. The BWS of type 1, which is similar to a ranking exercise, seems to be more affected by acquiescent responding and social desirability than the DCE, which introduces tradeoffs in the choice task and is likely to reveal more about true preferences.</p><p><strong>Highlights: </strong>Physician preference items (PPIs) are medical devices particularly exposed to physicians' choice with regard to type of product and supplier.Some established techniques of collecting preferences can be affected by response biases such as acquiescent responding and social desirability.Discrete choice experiments, introducing more complex tradeoffs in the choice task, are likely to mitigate such biases and reveal true physicians' preferences for PPIs.</p>","PeriodicalId":49839,"journal":{"name":"Medical Decision Making","volume":" ","pages":"886-900"},"PeriodicalIF":3.6,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10848602/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41218005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pricing Treatments Cost-Effectively when They Have Multiple Indications: Not Just a Simple Threshold Analysis. 当治疗有多种适应症时,为其定价具有成本效益:不仅仅是简单的阈值分析。
IF 3.6 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-10-01 Epub Date: 2023-09-12 DOI: 10.1177/0272989X231197772
Jeremy D Goldhaber-Fiebert, Lauren E Cipriano
<p><strong>Background: </strong>Economic evaluations of treatments increasingly employ price-threshold analyses. When a treatment has multiple indications, standard price-threshold analyses can be overly simplistic. We examine how rules governing indication-specific prices and reimbursement decisions affect value-based price analyses.</p><p><strong>Methods: </strong>We analyze a 2-stage game between 2 players: the therapy's manufacturer and the payer purchasing it for patients. First, the manufacturer selects a price(s) that may be indication specific. Then, the payer decides whether to provide reimbursement at the offered price(s). We assume known indication-specific demand. The manufacturer seeks to maximize profit. The payer seeks to maximize total population incremental net monetary benefit and will not pay more than their willingness-to-pay threshold. We consider game variants defined by constraints on the manufacturer's ability to price and payer's ability to provide reimbursement differentially by indication.</p><p><strong>Results: </strong>When both the manufacturer and payer can make indication-specific decisions, the problem simplifies to multiple single-indication price-threshold analyses, and the manufacturer captures all the consumer surplus. When the manufacturer is restricted to one price and the payer must make an all-or-nothing reimbursement decision, the selected price is a weighted average of indication-specific threshold prices such that reimbursement of more valuable indications subsidizes reimbursement of less valuable indications. With a single price and indication-specific coverage decisions, the manufacturer may select a high price where fewer patients receive treatment because the payer restricts reimbursement to the set of indications providing value commensurate with the high price. However, the manufacturer may select a low price, resulting in reimbursement for more indications and positive consumer surplus.</p><p><strong>Conclusions: </strong>When treatments have multiple indications, economic evaluations including price-threshold analyses should carefully consider jurisdiction-specific rules regarding pricing and reimbursement decisions.</p><p><strong>Highlights: </strong>With treatment prices rising, economic evaluations increasingly employ price-threshold analyses to identify value-based prices. Standard price-threshold analyses can be overly simplistic when treatments have multiple indications.Jurisdiction-specific rules governing indication-specific prices and reimbursement decisions affect value-based price analyses.When the manufacturer is restricted to one price for all indications and the payer must make an all-or-nothing reimbursement decision, the selected price is a weighted average of indication-specific threshold prices such that reimbursement of the more valuable indications subsidize reimbursement of the less valuable indications.With a single price and indication-specific coverage decisions, the manu
背景:治疗的经济评估越来越多地采用价格阈值分析。当一种治疗有多种适应症时,标准价格阈值分析可能过于简单化。我们研究了特定指示价格和报销决策的规则如何影响基于价值的价格分析。方法:我们分析了两个参与者之间的两阶段博弈:治疗的制造商和为患者购买治疗的付款人。首先,制造商选择可能是特定指示的价格。然后,付款人决定是否以所提供的价格提供补偿。我们假设已知指示特定需求。制造商寻求利润最大化。付款人寻求最大限度地增加总人口的净货币利益,并且不会支付超过其支付意愿阈值的费用。我们考虑了由制造商定价能力和付款人通过指示差异提供补偿能力的约束定义的游戏变体。结果:当制造商和付款人都能做出特定指示的决策时,问题简化为多个单一指示价格阈值分析,制造商捕获了所有消费者剩余。当制造商被限制为一个价格,并且付款人必须做出要么全有要么全无的补偿决定时,所选择的价格是指示特定阈值价格的加权平均值,使得更有价值指示的补偿补贴了价值较低指示的补偿。对于单一价格和适应症特定的覆盖范围决策,制造商可以选择高价格,其中较少的患者接受治疗,因为付款人将报销限制在提供与高价格相称的价值的适应症集合。然而,制造商可能会选择较低的价格,从而为更多的适应症和正的消费者盈余提供补偿。结论:当治疗有多种适应症时,包括价格阈值分析在内的经济评估应仔细考虑有关定价和报销决策的司法管辖区特定规则。亮点:随着治疗价格的上涨,经济评估越来越多地采用价格阈值分析来确定基于价值的价格。当治疗有多种适应症时,标准价格阈值分析可能过于简单。管辖特定指示价格和报销决定的特定管辖区规则影响基于价值的价格分析。当制造商被限制为所有适应症的一个价格,并且付款人必须做出全有或全无补偿的决定时,所选择的价格是适应症特定阈值价格的加权平均值,使得更有价值适应症的补偿补贴价值较低适应症的补偿。通过单一的价格和适应症特定的覆盖范围决定,制造商可以选择一个高价格,与第一个最佳解决方案相比,接受治疗的患者更少。还有一些情况是,制造商选择了更低的价格,从而为更多的适应症和正的消费者盈余提供补偿。
{"title":"Pricing Treatments Cost-Effectively when They Have Multiple Indications: Not Just a Simple Threshold Analysis.","authors":"Jeremy D Goldhaber-Fiebert, Lauren E Cipriano","doi":"10.1177/0272989X231197772","DOIUrl":"10.1177/0272989X231197772","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Economic evaluations of treatments increasingly employ price-threshold analyses. When a treatment has multiple indications, standard price-threshold analyses can be overly simplistic. We examine how rules governing indication-specific prices and reimbursement decisions affect value-based price analyses.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;We analyze a 2-stage game between 2 players: the therapy's manufacturer and the payer purchasing it for patients. First, the manufacturer selects a price(s) that may be indication specific. Then, the payer decides whether to provide reimbursement at the offered price(s). We assume known indication-specific demand. The manufacturer seeks to maximize profit. The payer seeks to maximize total population incremental net monetary benefit and will not pay more than their willingness-to-pay threshold. We consider game variants defined by constraints on the manufacturer's ability to price and payer's ability to provide reimbursement differentially by indication.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;When both the manufacturer and payer can make indication-specific decisions, the problem simplifies to multiple single-indication price-threshold analyses, and the manufacturer captures all the consumer surplus. When the manufacturer is restricted to one price and the payer must make an all-or-nothing reimbursement decision, the selected price is a weighted average of indication-specific threshold prices such that reimbursement of more valuable indications subsidizes reimbursement of less valuable indications. With a single price and indication-specific coverage decisions, the manufacturer may select a high price where fewer patients receive treatment because the payer restricts reimbursement to the set of indications providing value commensurate with the high price. However, the manufacturer may select a low price, resulting in reimbursement for more indications and positive consumer surplus.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;When treatments have multiple indications, economic evaluations including price-threshold analyses should carefully consider jurisdiction-specific rules regarding pricing and reimbursement decisions.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Highlights: &lt;/strong&gt;With treatment prices rising, economic evaluations increasingly employ price-threshold analyses to identify value-based prices. Standard price-threshold analyses can be overly simplistic when treatments have multiple indications.Jurisdiction-specific rules governing indication-specific prices and reimbursement decisions affect value-based price analyses.When the manufacturer is restricted to one price for all indications and the payer must make an all-or-nothing reimbursement decision, the selected price is a weighted average of indication-specific threshold prices such that reimbursement of the more valuable indications subsidize reimbursement of the less valuable indications.With a single price and indication-specific coverage decisions, the manu","PeriodicalId":49839,"journal":{"name":"Medical Decision Making","volume":" ","pages":"914-929"},"PeriodicalIF":3.6,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625719/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10213102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Constrained Optimization for Decision Making in Health Care Using Python: A Tutorial. 使用Python进行医疗保健决策的约束优化:教程。
IF 3.6 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-10-01 Epub Date: 2023-07-22 DOI: 10.1177/0272989X231188027
K H Benjamin Leung, Nasrin Yousefi, Timothy C Y Chan, Ahmed M Bayoumi

Highlights: This tutorial provides a user-friendly guide to mathematically formulating constrained optimization problems and implementing them using Python.Two examples are presented to illustrate how constrained optimization is used in health applications, with accompanying Python code provided.

亮点:本教程提供了一个用户友好的指南,用于从数学上制定约束优化问题并使用Python实现这些问题。提供了两个示例来说明如何在健康应用程序中使用约束优化,并提供了附带的Python代码。
{"title":"Constrained Optimization for Decision Making in Health Care Using Python: A Tutorial.","authors":"K H Benjamin Leung, Nasrin Yousefi, Timothy C Y Chan, Ahmed M Bayoumi","doi":"10.1177/0272989X231188027","DOIUrl":"10.1177/0272989X231188027","url":null,"abstract":"<p><strong>Highlights: </strong>This tutorial provides a user-friendly guide to mathematically formulating constrained optimization problems and implementing them using Python.Two examples are presented to illustrate how constrained optimization is used in health applications, with accompanying Python code provided.</p>","PeriodicalId":49839,"journal":{"name":"Medical Decision Making","volume":" ","pages":"760-773"},"PeriodicalIF":3.6,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625722/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10227647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Medical Decision Making
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1